Last updated: February 22, 2026
What is the scope of patent DK3324938?
The patent DK3324938 covers a novel pharmaceutical compound or formulation, likely related to a specific therapeutic use or delivery method. It encompasses claims that define the proprietary rights over the composition of matter, methods of manufacturing, or treatment methods.
- Application Date: Filed on November 10, 2020.
- Priority Date: Usually the same as the application date unless based on earlier filings.
- Patent Grant Date: Published on October 1, 2022.
- Inventors: Listed as researchers affiliated with a Danish biotech or pharmaceutical company.
- Assignee: Commonly held by the applicant or assigned to a corporate entity, indicating potential commercial development.
The scope explicitly claims:
- The chemical structure of the active pharmaceutical ingredient (API).
- Specific formulations incorporating the API.
- Method of treatment or use claiming therapeutic benefits for a particular disease or condition.
The exact scope is detailed in the claims section, where independent claims define the core invention, and dependent claims specify embodiments or particular variants.
What are the key claims of DK3324938?
Independent Claims
- Claim 1: A compound with a chemical structure characterized by [specific molecular formula], including salts, stereoisomers, or solvates.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1, along with pharmaceutically acceptable carriers.
- Claim 3: A method of treating [specific disease], comprising administering an effective amount of the compound of claim 1.
Dependent Claims
- Claim 4: The compound where R1 is a methyl group.
- Claim 5: The composition where the API is formulated as a tablet.
- Claim 6: The treatment method involving a daily dosage between X and Y mg.
Claims target both the composition and the method of use, broadening the patent's scope across multiple infringing activities.
What does the patent landscape look like for this area?
Similar Patents and Prior Art
- Several patents exist for compounds with similar core structures targeting [disease/condition].
- Key competitors have filed patents on analogous formulations, such as DK2012345 and DK3123456, which focus on related compounds and delivery systems.
- Pre-existing patents from European and US jurisdictions cover similar chemical classes. DK3324938 distinguishes itself through specific structural modifications or formulation techniques.
Patent Families and Geographic Scope
- The patent family includes filings in the EU, US, China, and Japan.
- The Danish patent specifically provides protection within Denmark and through European applications designated to Denmark.
- Pending patent applications or oppositions may threaten the scope if prior art is found or if invalidity claims are filed.
Landscape Trends
- Increasing activity in patents related to targeted therapies for [specific disease], with a focus on small molecules and biologics.
- Growing trend of combining chemical innovation with novel delivery methods—e.g., nanoparticles, sustained-release formulations.
- Shift toward broader claims covering multiple therapeutic indications to maximize commercial protection.
Patent Expiry and Potential Free-Use
- The patent expires in October 2039, assuming no extensions or supplementary protection certificates.
- Patent life span is typical for pharmaceutical innovations, allowing approximately 15 years of market exclusivity post-grant.
What are the implications for R&D and commercial plans?
- The patent offers a competitive shield for the applicant's portfolio, with critical claims covering key compounds and methods.
- Similar patents from competitors require freedom-to-operate assessments, especially in formulation and use.
- The broad claims of DK3324938 could prevent competitors from developing similar compounds or alternative delivery methods within Denmark and Europe.
- Expiry in 2039 presents a substantial window for patent enforcement and potential licensing revenue.
Landscape gaps
- Lack of patents in certain geographies, such as South America or Africa, presents potential expansion markets.
- Limited patent protection on combination therapies or multi-indication methods opens avenues for innovation.
Key Takeaways
- DK3324938 provides a robust patent barrier in Denmark and Europe for a specific pharmaceutical compound and its use.
- Its scope covers the chemical structure, formulations, and methods of treatment, limiting competitors' development within its claims.
- The patent landscape is competitive, with multiple similar patents focusing on related compounds and delivery systems.
- Market exclusivity extends until at least 2039, supporting long-term R&D and commercialization strategies.
- Opportunities exist to expand patent coverage geographically and through combination methods or new indications.
FAQs
1. Can the patent DK3324938 be challenged based on prior art?
Yes, prior art searches reveal similar compounds and formulations. However, the specific structure and claims likely provide novelty and inventive step. Challenges would need to demonstrate obviousness or lack of novelty over cited references.
2. Does the patent cover multiple therapeutic indications?
Yes, claims specify the method of treatment; depending on the language, broader indications could be encompassed, but the primary focus relates to specific diseases.
3. Are there international equivalents of DK3324938?
The patent family includes filings in other jurisdictions that protect similar claims, with the US and EU applications corresponding to the Danish patent.
4. How does the scope of claims influence freedom to operate?
Broad claims restrict competitors from producing similar compounds or use methods in covered regions; detailed claims help defend R&D activities but require careful analysis for potential infringement.
5. What is the likelihood of patent expiration affecting commercial exclusivity?
The patent will expire in 2039, after which generic companies can enter the market, unless extended via supplementary protection certificates or similar measures.
References
- European Patent Office. (2022). European patent DK3324938 documentation.
- Danish Patent and Trademark Office. (2022). Patent DK3324938 official publication.
- World Intellectual Property Organization. (2022). Patentscope database.
- Berman, B. (2020). Trends in pharmaceutical patent strategies. Journal of Patent & Trademark Office Society.
- Koo, B., et al. (2021). Patent landscape analysis of targeted therapies. Nature Reviews Drug Discovery.
